Phylo, Inc. announced on August 4, 2026 that Chugai Pharmaceutical Co., Ltd. will deploy Biomni Lab, Phylo’s agentic AI platform for biomedical research, across Chugai’s drug discovery workflows, covering four areas: single-cell analysis, human genetics, disease biology, and target evaluation. The Tokyo-based drugmaker, a Roche Group member listed on the Tokyo Stock Exchange’s Prime Market, joins what Phylo calls its founding group of customers for the platform. Under the collaboration, Biomni…